Listen
LUPKYNIS (voclosporine) - Active lupus nephritis
Opinions on drugs -
Posted on
Apr 14 2023
Reason for request
Inclusion
First assessment.
Key points
Unfavourable opinion on reimbursement in the MA indication: "Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN)".
Role in the care pathway?
LUPKYNIS (voclosporin) does not have a role in the care pathway in view of its poorly established efficacy.
Clinical Benefit
| Insufficient |
The clinical benefit provided by LUPKYNIS 7.9 mg (voclosporin), soft capsule is insufficient in the MA indication to be covered by national solidarity schemes given the available alternatives. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
